Serum Cystatin 4 combined with routine clinical laboratory indicators: A support vector machine diagnostic model for early screening of gastrointestinal tumors
- 1Department of Clinical Laboratory, Anhui Provincial Public Health Clinical Center, Hefei, Anhui, China
- 2Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University North District, Hefei, Anhui, China
Abstract
Gastrointestinal tumors lack non-invasive early screening tools, with most patients diagnosed at advanced stages. Serum tumor markers combined with machine learning show promise, but single markers have low specificity. This study aimed to construct a non-invasive diagnostic model using multiple laboratory variables. A retrospective study included 214 gastrointestinal tumor patients (observation group) and 130 non-tumor individuals (control group). Thirty-eight laboratory indicators were detected, and seven core variables (HCT, Age, TP, ALB, PLT, WBC, CST4) were identified via feature selection. Eleven machine learning algorithms were used to build models, with performance evaluated by AUC, sensitivity, specificity, calibration curves, and DCA. Serum CST4 levels were significantly higher in the observation group (P < 0.001, AUC = 0.706). The SVM model showed the best performance: AUC = 0.85 (95% CI: 0.78–0.92), sensitivity = 95.4% (95% CI: 0.87–0.98), specificity = 61.5% (95% CI: 0.52–0.71), PPV = 80.5% (95% CI: 0.74–0.86), NPV = 88.9% (95% CI: 0.81–0.94) in the test set. Calibration curves demonstrated high consistency (deviation < 5%), and DCA confirmed superior net benefits. SHapley Additive exPlanations (SHAP) analysis identified HCT, CST4, and Age as top contributors. This internally validated tool demonstrated promising preliminary performance for gastrointestinal tumor screening in high-risk populations (sensitivity 95.4%, specificity 61.5%). Due to its modest specificity, it is suitable as an auxiliary risk stratification tool for high-risk individuals but not for general population screening. External prospective multi-center validation is mandatory before clinical application.
Related
- Predicting severe high-altitude de-acclimatization syndrome from pre-return exposure dose and laboratory indicators: a prospective cohort study of 475 males
- From Laboratory Screening to Field Application: A Comprehensive Review of Biocontrol Strategies Against Aflatoxin Contamination.
- Diagnostic Value of Gastrointestinal Ultrasound (GIUS), Including Doppler and Contrast-Enhanced Ultrasound (CEUS), in the Assessment of Inflammatory Bowel Disease Activity: A Scoping Review
- Cross-platform multi-laboratory screening identifies HUWE1, USP33 and USP20 as negative-regulators of autophagy or mitophagy with relevance to neurodegeneration
- Assessing measurement uncertainty at laboratory network scale and its impact on diagnostic performance in the absence of a gold standard: application to ELISA tests for Coxiella burnetii in ruminants
BibTeX
@article{bi2026serum,
title = {{Serum Cystatin 4 combined with routine clinical laboratory indicators: A support vector machine diagnostic model for early screening of gastrointestinal tumors}},
author = {Huijuan Bi and Lina Yin and Wenhao Fang and Jilu Shen},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0353753},
url = {https://doi.org/10.1371/journal.pone.0353753},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serum Cystatin 4 combined with routine clinical laboratory indicators: A support vector machine diagnostic model for early screening of gastrointestinal tumors
AU - Huijuan Bi
AU - Lina Yin
AU - Wenhao Fang
AU - Jilu Shen
PY - 2026
DA - 2026/09/21
JO - PLOS One
DO - 10.1371/journal.pone.0353753
UR - https://doi.org/10.1371/journal.pone.0353753
AB - Gastrointestinal tumors lack non-invasive early screening tools, with most patients diagnosed at advanced stages. Serum tumor markers combined with machine learning show promise, but single markers have low specificity. This study aimed to construct a non-invasive diagnostic model using multiple laboratory variables. A retrospective study included 214 gastrointestinal tumor patients (observation group) and 130 non-tumor individuals (control group). Thirty-eight laboratory indicators were detected, and seven core variables (HCT, Age, TP, ALB, PLT, WBC, CST4) were identified via feature selection. Eleven machine learning algorithms were used to build models, with performance evaluated by AUC, sensitivity, specificity, calibration curves, and DCA. Serum CST4 levels were significantly higher in the observation group (P < 0.001, AUC = 0.706). The SVM model showed the best performance: AUC = 0.85 (95% CI: 0.78–0.92), sensitivity = 95.4% (95% CI: 0.87–0.98), specificity = 61.5% (95% CI: 0.52–0.71), PPV = 80.5% (95% CI: 0.74–0.86), NPV = 88.9% (95% CI: 0.81–0.94) in the test set. Calibration curves demonstrated high consistency (deviation < 5%), and DCA confirmed superior net benefits. SHapley Additive exPlanations (SHAP) analysis identified HCT, CST4, and Age as top contributors. This internally validated tool demonstrated promising preliminary performance for gastrointestinal tumor screening in high-risk populations (sensitivity 95.4%, specificity 61.5%). Due to its modest specificity, it is suitable as an auxiliary risk stratification tool for high-risk individuals but not for general population screening. External prospective multi-center validation is mandatory before clinical application.
SN - 1932-6203
ER -